Curever Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 29-10-2024
- Paid Up Capital ₹ 0.10 M
as on 29-10-2024
- Company Age 3 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 20.00 Cr
as on 29-10-2024
- Revenue -73.84%
(FY 2023)
- Profit 13.77%
(FY 2023)
- Ebitda 34.04%
(FY 2023)
- Net Worth -85.74%
(FY 2023)
- Total Assets -58.69%
(FY 2023)
About Curever Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company has closed loans amounting to ₹20.00 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Prabhat Agrawal, Kaushik Natesan, and Prashant Srivastava serve as directors at the Company.
- CIN/LLPIN
U24230MH2021PTC353725
- Company No.
353725
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 Jan 2021
- Date of AGM
05 Aug 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Curever Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Prabhat Agrawal  | Director | 19-Jan-2021 | Current |
| Kaushik Natesan | Director | 19-Jan-2021 | Current |
| Prashant Srivastava | Director | 04-Oct-2022 | Current |
Financial Performance and Corporate Structure Insights of Curever Pharma.
Curever Pharma Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 73.84% decrease. The company also saw a substantial improvement in profitability, with a 13.77% increase in profit. The company's net worth observed a substantial decline by a decrease of 85.74%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Curever Pharma?
In 2023, Curever Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Avenues Pharma Distributors Private LimitedActive 5 years 8 monthsPrabhat Agrawal is a mutual person
- Svmed Solutions Private LimitedActive 5 years 8 months
Prabhat Agrawal and Kaushik Natesan are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 31 Jan 2022 | ₹20.00 Cr | Satisfied |
How Many Employees Work at Curever Pharma?
Curever Pharma has a workforce of 14 employees as of Mar 23, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Curever Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Curever Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
